Observational analysis reveals higher approval costs for GLP-1 agonists used in weight loss versus diabetes, indicating inefficiencies.
Total hands-on time spent on GLP-1 agonists prescribed for weight loss was significantly longer compared with GLP-1 agonists for diabetes and other non-GLP-1 agonist medications. Additionally, GLP-1 agonists for weight loss had lower approval rates and higher cost per PA.
No takes yet. Share an insight, caveat, or question.
Pham et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: